Purpose: To evaluate the efficacy and safety of percutaneous nephrolithotomy (PCNL) for patients in the supine position vs prone position. Materials and Methods: Eligible studies were identified from electronic databases (Cochrane CENTRAL, Medline and EMBASE). The database search, quality assessment, and data extraction were independently performed by two reviewers. Efficacy (stone-free rate, operative time) and safety (complication, such as fever and transfusion rate) were explored by using Review Manager 5.0. Sensitivity analysis was performed to explore the influence of low-quality studies. Results: Two randomized controlled trials and two case-control studies including 389 patients met the inclusion criteria. Meta-analysis of extractable data showed that PCNL in the supine position was associated with a significantly shorter operative time than PCNL in the prone position (mean difference : −24.84; 95% confidence interval [CI]: −34.45 to −15.23; P < 0.00001). There was no difference between the positions with regard to success rate (odds ratio [OR]: 1.16; 95% CI: 0.68–1.48; P = 0.59), complication (OR: 1.09; 95% CI: 0.67–1.80; P = 0.72), transfusion rate (OR: 2.19; 95% CI: 0.93–5.13; P = 0.07), and fever rate (OR: 0.39; 95% CI: 0.13–1.16; P = 0.09). Conclusion: PCNL in the supine position took a shorter operative time than the prone position, but both positions appeared to be equivalent with regard to the stone-free rate and complication rate, transfusion rate, and fever rate. In brief, PCNL in the supine position is as effective and safe as PCNL in the prone position and was an alternate option for removal of renal calculi in PCNL.

In recent years, advancements in single-cell and spatial transcriptomics, which are highly regarded developments in the current era, particularly the emerging integration of single-cell and spatiotemporal transcriptomics, have enabled a detailed molecular comprehension of the complex regulation of cell fate. The insights obtained from these methodologies are anticipated to significantly contribute to the development of personalized medicine. Currently, single-cell technology is less frequently utilized for prostate cancer compared with other types of tumors. Starting from the perspective of RNA sequencing technology, this review outlined the significance of single-cell RNA sequencing (scRNA-seq) in prostate cancer research, encompassing preclinical medicine and clinical applications. We summarize the differences between mouse and human prostate cancer as revealed by scRNA-seq studies, as well as a combination of multi-omics methods involving scRNA-seq to highlight the key molecular targets for the diagnosis, treatment, and drug resistance characteristics of prostate cancer. These studies are expected to provide novel insights for the development of immunotherapy and other innovative treatment strategies for castration-resistant prostate cancer. Furthermore, we explore the potential clinical applications stemming from other single-cell technologies in this review, paving the way for future research in precision medicine.

Background: Systemic immune-inflammation index (SII) has recently emerged as a biomarker for the prognosis of a variety of malignant tumors. However, the role of SII in bladder cancer (BC) remains unclear. To this end, we performed a pooled analysis to investigate the prognostic value of preoperative SII in patients with BC.Methods: A comprehensive search of electronic databases (PubMed/Medline, Web of Science, Scopus, and Cochrane Central Register of Controlled Trials) was conducted to determine the eligible studies that were published until January 2022. Pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to evaluate the association between preoperative SII and the prognosis and clinicopathological characteristics of BC.Results: Ten studies with 7,087 patients were included in this analysis. SII was observed to be correlated with inferior overall survival (HR = 1.22, 95% CI 1.04–1.44, p = 0.013), cancer-specific survival (HR = 1.68, 95% CI 1.14–2.47, p = 0.009), and recurrence-free survival (HR = 1.29, 95% CI 1.03–1.61, p = 0.027). An increased preoperative SII was also associated with poor tumor differentiation, higher tumor stage, presence of lymph node involvement, and tumor size ≥3 cm (all p < 0.05).Conclusions: An elevated preoperative SII is significantly associated with worse survival outcomes and adverse pathological features in patients with BC. Hence, SII may serve as a strong independent prognostic predictor for patients with BC after surgery.